Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The bone loss in Parkinson's disease (PD) emerges as a non-motor symptom with motor and non-motor outcomes, such as fracture and musculoskeletal pain. Bone mineral density (BMD) is decreasing in patients with PD when compared to sex and age-matched healthy controls. The changes in BMD according to clinical subtypes of PD is unknown. The investigators are planning to compare the BMD status between the tremor dominant and postural instability and gait difficulty type of PD.
The investigators are planning to complete this study between January and February 2019. This study will be performed at Ordu University Education and Research Hospital, Neurology Department.
All patients admitted to the outpatient clinic will be evaluated in terms of inclusion criteria. The control group consisted of people who do not have any orthopedic, neurological or metabolic disorders which may affect the BMD.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tremor dominant type group | Tremor dominant type (TDT) group will consist of the patients with tremor premotor symptoms. | ||
| PIGD dominant type group | Postural instability and gait difficulty dominant type (PIGDT) group will consist of the patients with axial premotor symptoms. | ||
| Healthy control group | Healthy control group will consist of the subjects with same age and sex matched individuals in PD group. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Dual-energy X-ray absorptiometry (DEXA) | Bone mineral density will be dertermined using DEXA results. The results will be interpreted by WHO (World Health Organization) criteria. : T-score (T-score) is determined by DEXA method. A T-score value of more than minus means that there is excess bone loss.
| 10-15 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Hoehn and Yahr Scale | Disease progression will be assessed with Hoehn and Yahr Scale. The original scale included stages 1 through 5. Stage 0: No signs of disease. Stage 1: Unilateral symptoms only. Stage 2: Bilateral symptoms. No impairment of balance. Stage 3: Balance impairment. Mild to moderate disease. Physically independent. Stage 4: Severe disability, but still able to walk or stand unassisted. Stage 5: Needing a wheelchair or bedridden unless assisted. |
Not provided
For TDT and PIGDT PD group
Inclusion Criteria:
Clinical diagnosis of idiopathic Parkinson's disease Age of 40-85 years
Exclusion Criteria:
Having additional orthopedic and neurological disorders Having metabolic disease, Having steroid drug use
For Control group
The similar age and sex-matched healthy individuals who have no orthopedic, metabolic and neurological disorders, and steroid use will be included in the study.
Not provided
Not provided
The PD group will be selcted from Neurology Department, Movement Disorders Clinic.
The control group will be selected from community population.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sevim ACARÖZ CANDAN, PhD | Contact | 00905071027447 | fzt_acaroz@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Sevim ACARÖZ CANDAN | Ordu University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sevim ACARÖZ CANDAN | Ordu | Altinordu | 52100 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D001851 | Bone Diseases, Metabolic |
| D014202 | Tremor |
| D051346 | Mobility Limitation |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2 minutes |
| Unified Parkinson's Disease Rating Scale (UPDRS) - Section of Activities of Daily Living (ADL) | The UPDRS- ADL section evaluates the impact of Parkinson disease on ADL according to patient's perspective. The ADL section consists of 13 items for gathering information on the patient's own perception of functional impairment due to PD. Each item scores between 0-4. 0 means normal and 4 means severe impairment. The total score change between 0-52. High scores indicate severe impairment. | 10 minutes |
| Unified Parkinson's Disease Rating Scale (UPDRS) - Motor Section | Motor section of UPDRS determines the impairment due to the Parkinson's disease. Rigidity, bradykinesia and tremor items which are relating with upper extremity function will be assessed. Each item scores between 0-4. 0 means normal and 4 means severe impairment. The total score change between 0-56. | 10 minutes |
| Unified Parkinson's Disease Rating Scale (UPDRS) - non-motor Section | Non-motor section of UPDRS evaluates the impact of the non motor symptoms in PD. Each item scores between 0-4. 0 means normal and 4 means severe impairment. Total score changes between 0-52. | 5 minutes |
| Unified Parkinson's Disease Rating Scale (UPDRS) - complications Section | Complications section of UPDRS evaluates the complications after the levodopa treatment in PD. Each item scores between 0-4. 0 means normal and 4 means severe impairment. Total score changes between 0-24. | 5 minutes |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D020820 | Dyskinesias |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |